Mr. VanOort continued, "I am also delighted to announce that I have accepted the position of Chief Executive Officer of NeoGenomics and will no longer serve in an interim capacity. NeoGenomics is an exciting company with a strong management team. I am excited to continue to execute on the strategic initiatives we have put in place as we expand the Company's presence in many areas of cancer genetic testing across the country."

Robert Gasparini, President and Chief Scientific Officer, added, "We are off to a rapid start in building our Melanoma FISH testing capability pursuant to the agreement we entered into with Abbott Laboratories in July. We have expanded our California laboratory location and are just completing the build-out of a new full-service melanoma FISH laboratory. We are also well into the process of validating this new melanoma FISH test and expect to complete a comprehensive validation study on over 500 patient samples by the end of the year. We are currently working with four validation partners, each of which will also become our initial marketing partners. We expect to launch the melanoma FISH test in the first quarter of 2010 with our validation partners and then quickly follow this with a national roll-out.

Conference Call

The Company has scheduled a webcast and conference call to discuss their Q3 2009 results at 11:00 AM EDT today. Interested investors should dial (877) 407-9210 (domestic) and (201) 689-8049 (international) at least five minutes prior to the call. A replay of the conference call will be available until 11:59 PM on November 13, 2009 and can be accessed by dialing (877) 660-6853 (domestic) and 1 (201) 612-7415 (international). The playback conference ID Number is 336389 and the PIN Number is 286. The web-cast may be accessed under the Investor Relations section of our website at neogenomics or at>

Source: NeoGenomics, Inc.